Literature DB >> 1684778

Th0 cells in the thymus: the question of T-helper lineages.

A Bendelac1, R H Schwartz.   

Abstract

Although peripheral naive cells only secrete IL-2 upon primary stimulation, their presumptive immediate precursors, HSAlow CD4+8- thymocytes, can produce a large amount of the set of lymphokines usually associated with preactivated or memory CD4+ lymphocytes: IL-4, IL-5, IL-10 and gamma-IFN. This phenotype can be attributed to true virgin thymocytes and not only to recirculating lymphocytes, because it is found in newborn thymuses and in fetal thymic organ culture. This mature stage of CD4+8- thymocytes is itself preceded by an immature stage (HSAhigh) where only IL-2 and small amounts of gamma-IFN can be elicited by the combination of calcium ionophore and phorbol ester, but not by TCR cross-linking. CD8+4- thymocytes pass through a similar immature HSAhigh stage, where their pattern of lymphokine secretion is not yet differentiated from that of CD4+8- HSA high thymocytes. The subsets acquire their specific profiles at the HSAlow stage. We propose that recent thymic CD4+8- emigrant cells include a significant proportion of Th0 type cells, and that their role is critical to prime the immune system for IL-4 production, as well as to explain the longstanding observations of synergy between helper cell subpopulations in the periphery.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684778     DOI: 10.1111/j.1600-065x.1991.tb00610.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  12 in total

1.  Disparate effect of beige mutation on cytotoxic function between natural killer and natural killer T cells.

Authors:  M Bannai; H Oya; T Kawamura; T Naito; T Shimizu; H Kawamura; C Miyaji; H Watanabe; K Hatakeyama; T Abo
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

2.  Intensive generation of NK1.1- extrathymic T cells in the liver by injection of bone marrow cells isolated from mice with a mutation of polymorphic major histocompatibility complex antigens.

Authors:  R C Halder; T Kawamura; M Bannai; H Watanabe; H Kawamura; M K Mannoor; S R Morshed; T Abo
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

Review 3.  Stress and allergic diseases.

Authors:  Ninabahen D Dave; Lianbin Xiang; Kristina E Rehm; Gailen D Marshall
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

Review 4.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

5.  More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2/TH0 type.

Authors:  Koichi Sugimoto; Kenji Tamayose; Makoto Sasaki; Takashi Danbara; Yosuke Aikawa; Hideoki Ogawa; Naotake Sato; Eiji Tashiro; Kazuo Oshimi
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 6.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

7.  Disease-protected major histocompatibility complex Ea-transgenic non-obese diabetic (NOD) mice show interleukin-4 production not seen in susceptible Ea-transgenic and non-transgenic NOD mice.

Authors:  N Brenden; J Böhme
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

8.  Hydrocortisone inhibition of human interleukin-4.

Authors:  K A Byron; G Varigos; A Wootton
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

Review 9.  The Th1/Th2 paradigm: still important in pregnancy?

Authors:  Gérard Chaouat
Journal:  Semin Immunopathol       Date:  2007-06       Impact factor: 11.759

10.  Murine thymic CD4+ T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the V beta 8 T cell receptor gene family.

Authors:  K Hayakawa; B T Lin; R R Hardy
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.